The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2022 | Early intervention neoadjuvant immunotherapy in lung cancer
David Paul Carbone, MD, PhD, Ohio State University Comprehensive Cancer Center, Columbus, OH, provides an overview of the use of a combination of targeted and immunotherapies with surgery in early-stage lung cancer. Previously, about half of patients undergoing lobectomy or other lung cancer corrective surgery have experienced reoccurrence with poor prognoses. However recent advances in combination therapy can substantially increase the survival outlook for this cohort. This interview was recorded at the American Association for Cancer Research (AACR) Annual Meeting 2022, New Orleans, LA.
